{"id":"vga039","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, VGA039 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating type 2 diabetes.","oneSentence":"VGA039 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:33.220Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07115004","phase":"PHASE3","title":"Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)","status":"RECRUITING","sponsor":"Vega Therapeutics, Inc","startDate":"2025-10-15","conditions":"Von Willebrand Disease (VWD)","enrollment":60},{"nctId":"NCT05776069","phase":"PHASE1, PHASE2","title":"Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)","status":"RECRUITING","sponsor":"Vega Therapeutics, Inc","startDate":"2023-03-16","conditions":"Von Willebrand Diseases","enrollment":116}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VGA039","genericName":"VGA039","companyName":"Vega Therapeutics, Inc","companyId":"vega-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VGA039 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}